IDEAYA Biosciences Inc
NASDAQ:IDYA
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
25.19
47.13
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
IDEAYA Biosciences Inc
Wall Street
Price Targets
IDYA Price Targets Summary
IDEAYA Biosciences Inc
According to Wall Street analysts, the average 1-year price target for
IDYA
is 55.81 USD
with a low forecast of 27.27 USD and a high forecast of 68.25 USD.
IDYA Last Price Targets
IDEAYA Biosciences Inc
The latest public price target was made on Nov 5, 2024 by
Andrew Berens
from
Leerink Partners
,
who expects
IDYA
stock to
rise by 5%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
|
Andrew Berens
Leerink Partners
|
27
USD
Upside 5% |
1 month ago
Nov 5, 2024
|
Leerink Partners Downgrades Ideaya Biosciences (IDYA) to Market Perform
StreetInsider
|
David Dai
UBS
|
50
USD
Upside 95% |
1 month ago
Oct 24, 2024
|
UBS Starts Ideaya Biosciences (IDYA) at Buy
StreetInsider
|
Graig Suvannavejh
Mizuho Securities
|
55
USD
Upside 115% |
2 months ago
Sep 25, 2024
|
Mizuho Reiterates Outperform Rating on Ideaya Biosciences (IDYA)
StreetInsider
|
Corinne Jenkins
Goldman Sachs
|
48
USD
Upside 87% |
3 months ago
Sep 23, 2024
|
Ideaya Biosciences (IDYA) PT Raised to $48 at Goldman Sachs
StreetInsider
|
|
Justin Zelin
BTIG
|
62
USD
Upside 142% |
3 months ago
Sep 23, 2024
|
BTIG Reiterates Buy Rating on Ideaya Biosciences (IDYA)
StreetInsider
|
Ben Burnett
Stifel Nicolaus
|
66
USD
Upside 158% |
3 months ago
Sep 23, 2024
|
Ideaya Biosciences (IDYA) PT Lowered to $66 at Stifel
StreetInsider
|
|
Ben Burnett
Stifel Nicolaus
|
68
USD
Upside 166% |
3 months ago
Sep 10, 2024
|
Ideaya Biosciences (IDYA) PT Raised to $68 at Stifel
StreetInsider
|
Yigal Nochomovitz
Citigroup
|
58
USD
Upside 126% |
3 months ago
Aug 27, 2024
|
Ideaya Biosciences price target lowered to $58 from $60 at Citi
TheFly
|
Matthew Biegler
Oppenheimer
|
53
USD
Upside 107% |
4 months ago
Aug 7, 2024
|
Ideaya Biosciences (IDYA) PT Lowered to $53 at Oppenheimer
StreetInsider
|
Gregory Renza
RBC Capital
|
61
USD
Upside 138% |
5 months ago
Jul 10, 2024
|
Ideaya Biosciences price target raised to $61 from $53 at RBC Capital
TheFly
|
|
Graig Suvannavejh
Mizuho Securities
|
50
USD
Upside 95% |
5 months ago
Jul 8, 2024
|
Mizuho Starts Ideaya Biosciences (IDYA) at Outperform
StreetInsider
|
|
Ben Burnett
Stifel Nicolaus
|
63
USD
Upside 146% |
6 months ago
Jun 3, 2024
|
Ideaya Biosciences (IDYA) PT Raised to $63 at Stifel
StreetInsider
|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is IDYA's stock price target?
Price Target
55.81
USD
According to Wall Street analysts, the average 1-year price target for
IDYA
is 55.81 USD
with a low forecast of 27.27 USD and a high forecast of 68.25 USD.
What is IDEAYA Biosciences Inc's Revenue forecast?
Projected CAGR
51%
The
compound annual growth rate
of IDEAYA Biosciences Inc's revenue for the next 4 years is
51%.
You don't have any saved screeners yet
